On May 1, 2025, QbDVision, an Austin, Texas-based digital chemistry, manufacturing, and controls (CMC) platform purpose-built for biopharma organizations, announced a $13 million strategic investment round led by prior investors Northpond Ventures and S3 Ventures, along with Create Health Ventures and company insiders. Wilson Sonsini Goodrich & Rosati advised QbDVision on the transaction.

QbDVision is a cloud-based platform tailored for biopharma organizations that unifies product and manufacturing knowledge, automates key development workflows, and enhances data-driven decision-making to accelerate the transition from R&D to Commercial Manufacturing while ensuring quality and compliance. Currently, their customers include three of the six largest pharmaceutical and biotech companies worldwide. The company will use the additional capital to accelerate growth and enhance development of its digital CMC platform.

The Wilson Sonsini team that advised QbDVision on the transaction includes Matt Lyons and Tanner Kuenneth. 

For more information, please see QbDVision's blog post. Additional coverage can be found on AustinInno.